{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:36:04Z","timestamp":1790753764234,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007174","name":"Pfizer Inc Boulder","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007174","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejca.2021.04.028","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:22:28Z","timestamp":1622766148000},"page":"116-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)"],"prefix":"10.1016","volume":"152","author":[{"given":"Helen","family":"Gogas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Arance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mandal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Liszkay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8530-780X","authenticated-orcid":false,"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Krajsov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-2820","authenticated-orcid":false,"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna Chiarion","family":"Sileni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Loquai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Queirolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Groot","family":"Jan de Willem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abir Tadmouri","family":"Sellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Suissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7017-9865","authenticated-orcid":false,"given":"Juliette","family":"Murris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8215-4318","authenticated-orcid":false,"given":"Ashwin","family":"Gollerkeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3402-0478","authenticated-orcid":false,"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.04.028_bib1","series-title":"The Global Cancer Observatory","year":"2020"},{"key":"10.1016\/j.ejca.2021.04.028_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2021.04.028_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/bjc.2014.476","article-title":"Beyond BRAF: where next for melanoma therapy?","volume":"112","author":"Fedorenko","year":"2015","journal-title":"Br J Canc"},{"issue":"3","key":"10.1016\/j.ejca.2021.04.028_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/17512433.2019.1570847","article-title":"Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations","volume":"12","author":"Trojaniello","year":"2019","journal-title":"Expet Rev Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.028_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2021.04.028_bib6","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.04.028_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","article-title":"Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma","volume":"126","author":"Ascierto","year":"2020","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.04.028_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.10012","article-title":"ASCO 2020: Update on overall survival in COLUMBUS: a randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma","volume":"38","author":"Gogas","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.028_bib9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/pcmr.12647","article-title":"Quality-of-life outcomes in patients with advanced melanoma: a review of the literature","volume":"30","author":"Malkhasyan","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"issue":"4","key":"10.1016\/j.ejca.2021.04.028_bib10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.soc.2018.05.008","article-title":"Health-related quality of life: the impact on morbidity and mortality","volume":"27","author":"Sitlinger","year":"2018","journal-title":"Surg Oncol Clin"},{"issue":"13","key":"10.1016\/j.ejca.2021.04.028_bib11","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","volume":"16","author":"Grob","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.028_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2021.04.028_bib13","unstructured":"European organisation for research and treatment of cancer: EORTC quality of life questionnaire (EORTC QLQ-C30). https:\/\/qol.eortc.org\/questionnaires\/ (accessed May 27, 2021)."},{"issue":"10","key":"10.1016\/j.ejca.2021.04.028_bib14","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1002\/cncr.23424","article-title":"Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of\u00a0Cancer Therapy-Melanoma questionnaire","volume":"112","author":"Cormier","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2021.04.028_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejca.2011.05.017","article-title":"Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial","volume":"48","author":"Cella","year":"2012","journal-title":"Eur J Canc"},{"issue":"Suppl 2","key":"10.1016\/j.ejca.2021.04.028_bib16","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1111\/j.1524-4733.2007.00278.x","article-title":"Evaluating health-related quality of life in cancer clinical trials: the National Cancer\u00a0Institute of Canada Clinical Trials Group experience","volume":"10","author":"Osoba","year":"2007","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.028_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11136-013-0583-6","article-title":"Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?","volume":"24","author":"Anota","year":"2015","journal-title":"Qual Life Res"},{"issue":"8","key":"10.1016\/j.ejca.2021.04.028_bib18","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1524-4733.2009.00570.x","article-title":"Evaluating minimal important differences for the FACT-Melanoma quality of life questionnaire","volume":"12","author":"Askew","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.ejca.2021.04.028_bib19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejca.2018.09.005","article-title":"Brandberg Y; EORTC melanoma group and EORTC quality of life group. Interpreting European organisation for research and treatment for cancer quality of life questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma","volume":"104","author":"Musoro","year":"2018","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.04.028_bib20","first-page":"238","article-title":"A simple method for estimating confidence intervals for exposure adjusted incidence rate and its applications to clinical trials","volume":"6","author":"He","year":"2015","journal-title":"J Biometrics Biostat"},{"issue":"3","key":"10.1016\/j.ejca.2021.04.028_bib21","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/bimj.201400173","article-title":"Asymptotically robust variance estimation for person-time incidence rates","volume":"58","author":"Scosyrev","year":"2015","journal-title":"Biom J"},{"issue":"18","key":"10.1016\/j.ejca.2021.04.028_bib22","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2021.04.028_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1758834010395342","article-title":"Health-related quality of life and cancer clinical trials","volume":"3","author":"Osoba","year":"2011","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.028_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clindermatol.2011.11.005","article-title":"Psychological stress and melanoma: are we meeting our patients' psychological needs?","volume":"31","author":"Kasparian","year":"2013","journal-title":"Clin Dermatol"},{"issue":"Suppl 6","key":"10.1016\/j.ejca.2021.04.028_bib25","doi-asserted-by":"crossref","first-page":"vi51","DOI":"10.1093\/annonc\/mdp255","article-title":"A systematic review of health-related quality of life in cutaneous melanoma","volume":"20","author":"Cornish","year":"2009","journal-title":"Ann Oncol"},{"issue":"suppl_5","key":"10.1016\/j.ejca.2021.04.028_bib26","first-page":"v428","article-title":"Hospitalization rates in columbus part 1: a phase 3 trial of encorafenib (enco) plus binimetinib (bini) versus vemurafenib (vem) or enco in braf-mutant melanoma","volume":"28","author":"Arance","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.028_bib27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/bjc.2017.488","article-title":"Health-related quality of life impact of cobimetinib\u00a0in combination with vemurafenib in patients with\u00a0advanced or metastatic BRAFV600 mutation-positive melanoma","volume":"118","author":"Dr\u00e9no","year":"2018","journal-title":"Br J Canc"},{"issue":"7","key":"10.1016\/j.ejca.2021.04.028_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2015.03.004","article-title":"Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma","volume":"51","author":"Schadendorf","year":"2015","journal-title":"Eur J Canc"},{"issue":"12","key":"10.1016\/j.ejca.2021.04.028_bib29","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1002\/cam4.2248","article-title":"Clinical outcomes of BRAF plus MEK inhibition in melanoma: a meta-analysis and systematic review","volume":"8","author":"Yu","year":"2019","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.ejca.2021.04.028_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000491","article-title":"Gutzmer R Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management","volume":"4","author":"Heinzerling","year":"2019","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.028_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/14740338.2018.1390562","article-title":"The safety and efficacy of dabrafenib and\u00a0trametinib for the treatment of melanoma","volume":"17","author":"Knispel","year":"2018","journal-title":"Expet Opin Drug Saf"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2021.10.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T01:04:24Z","timestamp":1678669464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921002744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":31,"alternative-id":["S0959804921002744"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.028","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejca.2021.10.002","asserted-by":"object"}]},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}